On EXEL
The lack of an SPA ended the prospects of a near term approval for Cabo in CRPC. The stock has suffered as a result.
But there was something interesting in the release that almost everyone is overlooking (at least in public discussions), namely that 306 and 307 will use a 60mg dose. Unless the company is a total fraud as DD likes to imply, that dose selection is meaningful. The company knows how testing is going in many cases. Smith is moving from a 40mg dose to testing a 20mg dose with the prospect of moving to a 14mg dose.
In the MTC trial the dosing started at 175mg with ugly side effects, SE's that were tolerable when weighed against disease progression which would have been worse.
The possibility that far lower doses may be effective in CRPC or other cancers suggests there is a market for Cabo if these lower doses prove effective.
Let the evidence accumulate.
ij
Market Data 
Markets 
AI
